Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Scholar Rock Holding Corporation - Common Stock (NQ:SRRK)

30.70 -1.84 (-5.65%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 995,585
Open 30.83
Bid (Size) 29.50 (5)
Ask (Size) 32.08 (1)
Prev. Close 32.54
Today's Range 29.86 - 32.13
52wk Range 6.760 - 46.98
Shares Outstanding 93,823,678
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy
From Scholar Rock
Via Business Wire
Scholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment
Scholar Rock will present new Phase 3 SAPPHIRE trial data on apitegromab at the 2025 MDA conference, highlighting efficacy and safety in SMA treatment. 
Via Benzinga

Performance

YTD
-30.5%
-30.5%
1 Month
-15.3%
-15.3%
3 Month
-30.5%
-30.5%
6 Month
+317.7%
+317.7%
1 Year
+95.3%
+95.3%

More News

Read More
Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
From Scholar Rock
Via Business Wire
Earnings Scheduled For February 27, 2025
Via Benzinga
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress
From Scholar Rock
Via Business Wire
Scholar Rock to Participate in Upcoming Investor Conferences
From Scholar Rock
Via Business Wire
Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
From Scholar Rock
Via Business Wire
What's going on in today's after hours session
Via Chartmill
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025
From Scholar Rock
Via Business Wire
Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)
From Scholar Rock
Via Business Wire
Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition
From Scholar Rock
Via Business Wire
Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth
Via Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Scholar Rock Highlights 2025 Strategic Priorities
From Scholar Rock
Via Business Wire
Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Scholar Rock
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study
Via Benzinga

Frequently Asked Questions

Is Scholar Rock Holding Corporation - Common Stock publicly traded?
Yes, Scholar Rock Holding Corporation - Common Stock is publicly traded.
What exchange does Scholar Rock Holding Corporation - Common Stock trade on?
Scholar Rock Holding Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Scholar Rock Holding Corporation - Common Stock?
The ticker symbol for Scholar Rock Holding Corporation - Common Stock is SRRK on the Nasdaq Stock Market
What is the current price of Scholar Rock Holding Corporation - Common Stock?
The current price of Scholar Rock Holding Corporation - Common Stock is 30.70
When was Scholar Rock Holding Corporation - Common Stock last traded?
The last trade of Scholar Rock Holding Corporation - Common Stock was at 04/03/25 04:00 PM ET
What is the market capitalization of Scholar Rock Holding Corporation - Common Stock?
The market capitalization of Scholar Rock Holding Corporation - Common Stock is 2.88B
How many shares of Scholar Rock Holding Corporation - Common Stock are outstanding?
Scholar Rock Holding Corporation - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.